Caption Management’s Theravance Biopharma TBPH Stock Holding History

Caption Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.04M	Buy	+248,700	New	+$4.4M	0.02%	591
2023 Q1	–	Sell	-50,000	Closed	-$561K	–	1535
2022 Q4	$561K	Sell	50,000 -10,000	-17%	-$105K	0.01%	897
2022 Q3	$608K	Buy	+60,000	New	+$562K	0.01%	1021
2022 Q2	–	Sell	-63,300	Closed	-$605K	–	1821
2022 Q1	$605K	Buy	+63,300	New	+$620K	0.01%	1105
2021 Q3	–	Sell	-15,000	Closed	-$217K	–	1799
2021 Q2	$217K	Sell	15,000 -15,000	-50%	-$282K	﹤0.01%	1169
2021 Q1	$611K	Buy	+30,000	New	+$570K	0.01%	771
2020 Q4	–	Sell	-30,000	Closed	-$443K	–	1236
2020 Q3	$443K	Buy	30,000 +9,000	+43%	+$169K	0.01%	796
2020 Q2	$441K	Buy	21,000 +8,500	+68%	+$218K	0.01%	694
2020 Q1	$289K	Buy	+12,500	New	+$313K	0.02%	648
2019 Q3	–	Sell	-100,000	Closed	-$1.63M	–	883
2019 Q2	$1.63M	Buy	100,000 +50,000	+100%	+$1.01M	0.08%	289
2019 Q1	$1.13M	Buy	+50,000	New	+$1.27M	0.06%	331

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's TBPH Position: Q1 2026 in Review

Caption Management opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 163,704 shares worth $2.66M. The stake represents 0.02% of the portfolio and ranks #741 among its holdings. This is a return to the name: Caption Management previously reported a position in TBPH as recently as Q4 2022.

Caption Management first reported a position in TBPH in Q1 2019 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Caption Management held 163,704 shares of Theravance Biopharma worth $2.66M as of Q1 2026.
Theravance Biopharma was a new Caption Management position in Q1 2026.
Theravance Biopharma made up 0.02% of Caption Management's portfolio in Q1 2026, its #741 holding.
Caption Management first reported a position in Theravance Biopharma in Q1 2019 and has held it in 8 quarters since.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.